September 11, 2006 02:31 ET

DSM invests in personal care company Sol-Gel Technologies

HEERLEN, NETHERLANDS -- (MARKET WIRE) -- September 11, 2006 --

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has invested USD 2 mln in Sol-Gel Technologies Ltd., a private early-stage company committed to the development and commercialization of safer and more effective healthcare products. Sol-Gel's technology platform is of interest to DSM for its further development of skin care and dermatology applications as part of its ambitions in the field of Personal Care.

Sol-Gel develops (ingredients for) sunscreens, anti-acne and anti-ageing products which are based on their proprietary sol-gel technology. This technology enables room temperature entrapment of organic and bioactive molecules in silica glass beads. The ingredients can thereby be safely isolated and their delivery can be controlled, a potentially valuable innovation for the pharmaceutical and cosmetic markets. The company has received exclusive worldwide licenses and patents, plus patents pending, for this technology.

In addition to the investment DSM and Sol-Gel Technologies intend to explore possible joint development activities and other collaborations, not only in the field of Personal Care but also in DSM's strategic markets Animal and Human Nutrition.

DSM offers its customers in the cosmetic industry a world-leading portfolio of vitamins, bioactive ingredients and UV filters. To stay at the forefront DSM is dedicated to the discovery and development of technically superior new ingredients for skin care, sun care and hair care products, both in its own R&D department and in cooperation with innovative players such as Sol-Gel Technologies.

DSM Venturing

DSM Venturing is an active investor in start-up companies and Venture Capital Funds in the fields of Nutrition, Pharma and Performance Materials. DSM Venturing's mission is to explore emerging markets and technologies in order to enhance DSM's product portfolio and create value. For more information about DSM Venturing see

Sol Gel Technologies Ltd.

Sol-Gel Technologies Ltd. is a groundbreaking nanoengineering company that has developed proprietary platform technology with potential commercial applications in many different markets. Sol-Gel was founded in 1997 and is based in Israel and in the USA. The company includes a team of distinguished scientists, engineers and business managers and operates a state-of-the-art GMP plant capable of producing commercial quantities of its nanotechnology products. Sol-Gel's first commercial product, UV-Pearls™, is already being sold to some of the world's leading cosmetic manufacturers.


DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company creates innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end markets and applications such as human and animal nutrition and health, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. Market-driven growth, innovation and increased presence in emerging economies are key drivers of this strategy. The group has annual sales of over EUR 8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa and the Americas. More information about DSM can be found at

For more information:

DSM Corporate Communications        DSM Investor Relations
Nelleke Barning                     Dries Ausems
tel. +31 (0) 45 5782017             tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680              fax +31 (0) 45 5782595
e-mail      e-mail

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information